Dapagliflozin And Pulmonary Artery Hemodynamics in Heart Failure With

Status Not yet recruiting

Clinical Trial Summary

The focus of this study is to investigate the use of Dapagliflozin in HFrEF (NYHA II-IV) patients with or without diabetes who have CardioMEMS® implanted to assess the impact on pulmonary artery pressure measurements after 12 weeks of therapy.

Clinical Trial Description

Prior studies have demonstrated an association between the use of sodium-glucose cotransporter 2 (SGLT-2) inhibitors for diabetic patients and reductions in composite primary outcomes of cardiovascular mortality, nonfatal myocardial infarction, or nonfatal stroke, as well as reductions in heart failure among patients with diabetes. The 2019 DAPA-HF trial studied whether the addition of the SCLT-2 inhibitor dapagliglozin could benefit patients with heart failure with reduced ejection fraction (HFrEF), either with or without diabetes. Results indicated that that SGLT-2 inhibitors resulted in 4.9% absolute reduction in the cardiovascular death or worsening heart failure and a 2.3% absolute reduction in all-cause mortality in patients with and without diabetes. Dapagliflozin is FDA approved to reduce the risk of cardiovascular death or hospitalization in patients with HFrEF with or without Type 2 diabtes. The mechanisms of cardiovascular benefit remain unclear, however it is likely to be driven by a reduction in heart failure death given that rates of myocardial infarction were similar between treatment arms.

The CardioMEMS® system is an implantable device that can measure pulmonary artery systolic, diastolic and mean pressure on a daily basis. It has been shown convincingly that monitoring the MEMS device results in reduced pulmonary pressures and in turn a reduction in heart failure hospitalizations.

The focus of this study is to investigate the use of Dapagliflozin in HFrEF (NYHA II-IV) patients with or without diabetes who have CardioMEMS® implanted to assess the impact on pulmonary artery pressure measurements after 12 weeks of therapy. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT04570865
Study type	Interventional
Source	Scripps Health
Contact
Status	Not yet recruiting
Phase	Phase 4
Start date	December 1, 2020
Completion date	February 1, 2022

View Details

See also
Status	Clinical Trial	Phase
Withdrawn	`NCT03227393` - The Effect of Yoga on Cardiac Sympathetic Innervation Evaluated by I-123 mIBG	N/A
Recruiting	`NCT04528004` - Mechanistic Studies of Nicotinamide Riboside in Human Heart Failure	Early Phase 1
Recruiting	`NCT04703842` - Modulation of SERCA2a of Intra-myocytic Calcium Trafficking in Heart Failure With Reduced Ejection Fraction	Phase 1/Phase 2
Recruiting	`NCT04522609` - Electrostimulation of Skeletal Muscles in Patients Listed for a Heart Transplant	N/A
Completed	`NCT05475028` - Network Medicine Approaches to Classify Heart Failure With PReserved Ejection Fraction by Signatures of DNA Methylation and Point-of-carE Risk calculaTors (PRESMET)
Not yet recruiting	`NCT05988749` - Digital Remote Home Monitoring for Heart Failure	N/A
Not yet recruiting	`NCT06240403` - Digoxin and Senolysis in Heart Failure and Diabetes Mellitus	Phase 2
Recruiting	`NCT04950218` - The Psoriasis Echo Study
Suspended	`NCT04701112` - Acute Hemodynamic Effects of Pacing the His Bundle in Heart Failure	N/A
Completed	`NCT03305692` - ECG Belt vs. Echocardiographic Optimization of CRT	N/A
Recruiting	`NCT05933083` - MCNAIR Study: coMparative effeCtiveness of iN-person and teleheAlth cardIac Rehabilitation	N/A
Enrolling by invitation	`NCT03903107` - The Fluoroless-CSP Trial Using Electroanatomic Mapping	N/A
Withdrawn	`NCT04872959` - TRANSFORM Heart Failure With Reduced Ejection Fraction	N/A
Completed	`NCT02920918` - Treatment of Diabetes in Patients With Systolic Heart Failure	Phase 4
Completed	`NCT02334891` - Kyoto Congestive Heart Failure Study
Recruiting	`NCT03553303` - Pharmacodynamic Effects of Sacubitril/Valsartan on Natriuretic Peptides, Angiotensin and Neprilysin	Phase 4
Recruiting	`NCT04083690` - Multi-lead ECG to Effectively Optimize Resynchronization Devices: New CRT Recipients	N/A
Recruiting	`NCT03830957` - Efficacy and Safety of Ivabradine to Reduce Heart Rate Prior to Coronary CT-angiography in Advanced Heart Failure: Comparison With β-Blocker	N/A
Recruiting	`NCT06121323` - Physiological Effects of Lactate in Individuals With Chronic Heart Failure	N/A
Completed	`NCT03351283` - Effect of Sodium Intake on Brain Natriuretic Peptide Levels in Patients With Heart Failure	N/A

Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.

Dapagliflozin And Pulmonary Artery Hemodynamics in Heart Failure With Reduced Ejection Fraction Patients With CardioMEMS® — DAPA-MEMS

Clinical Trial Summary

Clinical Trial Description

Study Design

Related Conditions & MeSH terms